Molika Ashford

New data from a Japanese Phase II study have solidified a path forward for pertuzumab plus trastuzumab in HER2-positive colorectal cancer patients.

As economic and practical challenges of next-gen sequencing have eased in recent years, more groups are bringing comprehensive cancer genomic testing in house.

The company will compete against established comprehensive genomic sequencing assays, but hopes to provide better immunotherapy prediction.

The company believes its findings are the first to show that quantifying ctDNA changes can stratify high-risk colorectal cancer patients into better and worse prognostic groups.

A Spanish team is hoping it can further validate promising early results using TCR characteristics to predict the success or failure of pre-surgery chemoimmunotherapy.

The company said the results highlight precision oncology implementation challenges and its test's ability to help overcome these issues.

The company is working with three institutions to recruit about 1,200 case-control participants for its validation study, with plans to launch an LDT next year.

The technology, developed by researchers at Stanford, showed strong performance in a new study of lymphoma, and early data for solid tumors is already available.

Investigators analyzed blood samples from patients at two time points after curative-intent surgery, finding that ctDNA MRD status was highly predictive of outcome.

The firm announced the new test, Guardant360 Response, alongside its launch of its Guardant360 TissueNext tumor tissue genomic profiling product.